Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0L3GE)

Drug Name
(+/-)-nantenine Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
181743
CAS Number
CAS 42971-15-3
TTD Drug ID
DM0L3GE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Preclinical Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [2]
Dihydroergocristine DM5SQ1G Alcohol dependence 6C40.2 Approved [3]
Brimonidine DMQLT4N Ocular hypertension 9C61.01 Approved [4]
Amosulalol DML8QSZ Hypertension BA00-BA04 Approved [5]
Amezinium DM6I2WQ Hypotension BA20-BA21 Approved [6]
Propylhexedrine DMTBW2O Obesity 5B81 Approved [7]
Tetrahydrozoline DMT57WC Ocular disease 1F00.1Z Approved [8]
Rilmenidine DM13PQW Hypertension BA00-BA04 Approved [9]
Xylometazoline DMKV32D Allergic rhinitis CA08.0 Phase 4 [10]
TNX-102 DMO1234 Fibromyalgia MG30.01 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D3 receptor (D3R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cariprazine DMJYDVK Bipolar disorder 6A60 Approved [12]
Pramipexole DMNMW9R Parkinson disease 8A00.0 Approved [13]
Ropinirole DMA6S1D Parkinson disease 8A00.0 Approved [13]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [14]
P2B-001 DM9PVHX Parkinson disease 8A00.0 Phase 3 [15]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [16]
ONC201 DMM5SCF Endometrial cancer 2C76 Phase 2 [17]
TAK-906 DMBQD9H Diabetic gastroparesis DA41.00 Phase 2 [18]
GSK598809 DMGU05N Drug abuse 6C4G.1Z Phase 2 [19]
GSK618334 DMJPXZ4 Drug abuse 6C4G.1Z Phase 1 [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1B receptor (HTR1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [20]
Eletriptan DMW649X Migraine 8A80 Approved [13]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [13]
Frovatriptan DM7RE8P Migraine 8A80 Approved [13]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [13]
Naratriptan DMO50U2 Headache 8A80-8A84 Approved [21]
Prolixin decanoate DMMJ1IS Schizophrenia 6A20 Approved [13]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [22]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [23]
[N-methyl-3H(3)]AZ-10419369 DMSCV02 Mood disorder 6A60-6E23 Phase 1 [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [25]
Eletriptan DMW649X Migraine 8A80 Approved [13]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [13]
Frovatriptan DM7RE8P Migraine 8A80 Approved [13]
Sumatriptan DMVYXR8 Cluster headache 8A81.0 Approved [26]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [27]
Almogran DM7I64Z Migraine 8A80 Approved [28]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [29]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [16]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-2A (ADRA2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lofexidine DM1WXA6 Heroin and opiate withdrawal 6C43 Approved [30]
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [2]
Connexyn DMF29Q5 Attention deficit hyperactivity disorder 6A05.Z Approved [31]
Guanfacine DMPN5IH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [32]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [33]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [34]
DSP-1200 DM4WSHG Depression 6A70-6A7Z Phase 1 [16]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [35]
NMI-870 DMU596F Sexual dysfunction HA00-HA01 Discontinued in Phase 2 [36]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 5A receptor (HTR5A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [38]
SEROTONIN DMOFCRY Discovery agent N.A. Investigative [39]
5-CT DM260KD Discovery agent N.A. Investigative [40]
TFMPP DMAC8TP Discovery agent N.A. Investigative [41]
5,6-dichloro-3,4-dihydroquinazolin-2-amine DMN1S35 Discovery agent N.A. Investigative [42]
MPDT DMYX31S Discovery agent N.A. Investigative [43]
5-chloro-3,4-dihydroquinazolin-2-amine DMKEFJ0 Discovery agent N.A. Investigative [42]
EDMT DMS3AXK Discovery agent N.A. Investigative [43]
5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine DM7FZU2 Discovery agent N.A. Investigative [42]
[3H]5-CT DMEAHFZ Discovery agent N.A. Investigative [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [45]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [46]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [47]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [48]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [47]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [49]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [50]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [46]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [51]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D1 receptor (D1R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Phenyltoloxamine DMKAEQW Allergy 4A80-4A85 Approved [53]
Pergolide DM14MAE Parkinson disease 8A00.0 Approved [13]
Methylergonovine DMBEX4O Spontaneous abortion JA00.0 Approved [54]
Fenoldopam DMFAOKP Hypertension BA00-BA04 Approved [55]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [56]
Ecopipam DMS9R43 Cocaine addiction 6C45.2 Phase 3 [57]
DAS-431 DMM3BPL Dementia 6D80-6D86 Phase 2 [58]
Dihydrexidine DMACPQO Psychotic disorder 6A20-6A25 Phase 1/2 [59]
Lu AF28996 DMY572G Parkinson disease 8A00.0 Phase 1 [60]
BAM-1110 DMPMKUF Parkinson disease 8A00.0 Discontinued in Phase 2 [61]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D4 receptor (D4R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clozapine DMFC71L Schizophrenia 6A20 Approved [13]
Phenyltoloxamine DMKAEQW Allergy 4A80-4A85 Approved [53]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [14]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [16]
L-745,870 DMTGR25 Psychotic disorder 6A20-6A25 Phase 2 [62]
NGD 94-1 DMM1Y8F Schizophrenia 6A20 Phase 1 [63]
ABT-724 DMDQVY4 Erectile dysfunction HA01.1 Discontinued in Phase 2 [64]
Lu-35138 DMQ7A35 Psychotic disorder 6A20-6A25 Discontinued in Phase 2 [65]
NGD-94-4 DMZ9WLO Schizophrenia 6A20 Discontinued in Phase 1 [66]
PD-165167 DMD0GB4 Schizophrenia 6A20 Preclinical [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Serotonin transporter (SERT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [67]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [68]
Fluoxetine DM3PD2C Bipolar depression Approved [13]
Vortioxetine DM6F1PU Major depressive disorder 6A70.3 Approved [12]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [69]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [70]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [71]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [13]
Nortriptyline DM4KDYJ Depression 6A70-6A7Z Approved [13]
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1B (ADRA1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methamphetamine DMPM4SK Anxiety Approved [72]
Propericiazine DME9JNL Psychiatric disorder 6E8Z Approved [73]
Methoxamine DMF5XQH Hypertension BA00-BA04 Approved [74]
Phendimetrazine DM6TS1N Obesity 5B81 Approved [75]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [34]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [76]
Sunepitron DM6M8ZX N. A. N. A. Discontinued in Phase 3 [77]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [35]
SOU-001 DMPAEK5 Urinary incontinence MF50.2 Discontinued in Phase 2 [78]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [79]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histamine H2 receptor (H2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [80]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [81]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [81]
Nizatidine DMGFV3Z Acid-reflux disorder DA22 Approved [82]
Betazole DMUFGAY Gastric secretory disorder DD90 Approved [83]
Ebrotidine DMV5KR3 Duodenal ulcer DA63 Withdrawn from market [84]
Pibutidine DMXSTRM Ulcerative colitis DD71 Discontinued in Phase 3 [85]
Osutidine DMN7TL8 Duodenal ulcer DA63 Discontinued in Phase 3 [86]
KU-1257 DMZMFX6 Duodenal ulcer DA63 Discontinued in Phase 3 [87]
Lavoltidine DMTY5VE Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [88]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2B receptor (HTR2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [89]
Triflupromazine DMKFQJP Nausea MD90 Approved [90]
Minaprine DM0EP7M Depression 6A70-6A7Z Approved [91]
SPN-812 DMTV7XH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [92]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [93]
PRX-08066 DMR7H2V Pulmonary arterial hypertension BB01.0 Phase 2 [94]
Pyrimidine derivative 29 DMVOYJ8 N. A. N. A. Patented [95]
Pyrimidine derivative 26 DM90WKN N. A. N. A. Patented [95]
Pyrimidine derivative 23 DM5MLQU N. A. N. A. Patented [95]
Pyrimidine derivative 25 DM51MFS N. A. N. A. Patented [95]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [89]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [96]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [97]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [12]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [98]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [99]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [100]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [101]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [102]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-2B (ADRA2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [2]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [34]
AGN-199981 DMP5Y1A Neuropathic pain 8E43.0 Phase 2 [103]
INDORAMIN DMNSJFD Hypertension BA00-BA04 Withdrawn from market [104]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [35]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [37]
A-80426 DMBC3DG N. A. N. A. Terminated [105]
WB-4101 DMQU8B1 N. A. N. A. Terminated [106]
SK&F-104078 DMRADBU N. A. N. A. Terminated [104]
R-226161 DM4BP7S Discovery agent N.A. Investigative [107]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor beta-1 (ADRB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Propranolol DM79NTF Angina pectoris BA40 Approved [108]
Epinephrine DM3KJBC Acute asthma CA23 Approved [109]
Norepinephrine DMOUC09 Alopecia ED70 Approved [110]
Atenolol DMNKG1Z Angina pectoris BA40 Approved [111]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [111]
Metoprolol DMOJ0V6 Acute coronary syndrome BA41 Approved [111]
Timolol DM3NXRU High blood pressure BA00 Approved [112]
Isoproterenol DMK7MEY Atrioventricular block Approved [113]
Betaxolol DM6EUL5 Hypertension BA00-BA04 Approved [114]
Sotalol DML60TN Sinus rhythm disorder BC9Y Approved [115]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D5 receptor (D5R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Phenyltoloxamine DMKAEQW Allergy 4A80-4A85 Approved [53]
LE-300 DMGJL16 Schizophrenia 6A20 Preclinical [63]
ZD-3638 DM6M9GC Schizophrenia 6A20 Terminated [63]
GMC-283 DMT1RH6 Schizophrenia 6A20 Terminated [63]
ISOCLOZAPINE DM52CPU Discovery agent N.A. Investigative [116]
FLUMEZAPINE DMW0HOG Discovery agent N.A. Investigative [117]
ISOLOXAPINE DMH1BN4 Discovery agent N.A. Investigative [118]
1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine DMOL2Y0 Discovery agent N.A. Investigative [116]
1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine DMD2NXL Discovery agent N.A. Investigative [53]
STEPHOLIDINE DMGMXQC Discovery agent N.A. Investigative [119]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Opioid receptor mu (MOP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [120]
Morphine DMRMS0L Advanced cancer 2A00-2F9Z Approved [121]
Hydromorphone DMHP21E Back pain ME84.Z Approved [122]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [123]
Fentanyl DM8WAHT Analgesia MB40.8 Approved [124]
Alfentanil DMVO0UB Anaesthesia 9A78.6 Approved [125]
Naloxegol DML0B41 Opioid-induced constipation DB32.1 Approved [126]
Eluxadoline DMYZ0P1 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [127]
Nalfurafine hcl DMA9DHW Uremic pruritus EC90.10 Approved [128]
Oxycodone DMXLKHV Osteoarthritis FA00-FA05 Approved [129]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1D (ADRA1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxazosin DM9PLRH Benign prostatic hyperplasia GA90 Approved [130]
Armodafinil DMGB035 Malignant glioma 2A00.0 Approved [131]
Alfuzosin DMZVMKF Benign prostatic hyperplasia GA90 Approved [132]
Moxisylyte DMFCLYW Erectile dysfunction HA01.1 Approved [133]
Terazosin DM3JCVS Benign prostatic hyperplasia GA90 Approved [134]
Bunazosin DM4I8O7 Glaucoma/ocular hypertension 9C61 Approved [135]
Trimazosin DM1QLST Congestive heart failure BD10 Approved [136]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [34]
DL-017 DMM8GZT Hypertension BA00-BA04 Phase 1 [137]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [138]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D2 receptor (D2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [139]
Haloperidol DM96SE0 Delirium Approved [140]
Perphenazine DMA4MRX Schizophrenia 6A20 Approved [141]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [142]
Domperidone DMBDPY0 Gastrointestinal disease DE2Z Approved [143]
Levodopa DMN3E57 Parkinson disease 8A00.0 Approved [144]
Quetiapine DM1N62C Anorexia nervosa cachexia 6B80 Approved [145]
Pimozide DMW83TP Schizophrenia 6A20 Approved [146]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [147]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [97]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 7 receptor (HTR7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [16]
JNJ-18038683 DMV1T59 Major depressive disorder 6A70.3 Phase 2 [148]
AVN-101 DMOGFNI Cognitive impairment 6D71 Phase 2 [149]
ATI-9242 DM6GKMU Schizophrenia 6A20 Phase 1 [150]
PMID30124346-Compound-34TABLE4 DM2G3VE Attention deficit hyperactivity disorder 6A05.Z Patented [138]
PMID30124346-Compound-13TABLE4 DMHTJVA Attention deficit hyperactivity disorder 6A05.Z Patented [138]
Carbamide derivative 2 DMW5GI3 N. A. N. A. Patented [151]
4-oxadiazole derivative 1 DMWFHKR N. A. N. A. Patented [151]
SB-269970 DM8WTGA Sleep-wake disorder 7A00-7B2Z Terminated [152]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [153]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2C receptor (HTR2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [89]
Lorcaserin DMG6OYJ Obesity 5B81 Approved [154]
Tramadol DMRQD04 Osteoarthritis FA00-FA05 Approved [155]
Mirtazapine DML53ZJ Depression 6A70-6A7Z Approved [156]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [157]
Methysergide DM1EF73 Migraine 8A80 Approved [158]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [22]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [159]
SR46349B DM1ODMR Primary insomnia 7A00 Phase 3 [160]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [93]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SILODOSIN DMJSBT6 Benign prostatic hyperplasia GA90 Approved [161]
NAFTOPIDIL DMQ8R4E Hypertension BA00-BA04 Approved [161]
Tamsulosin DM5QF9V Benign prostatic hyperplasia GA90 Approved [13]
Xatral DMLHOA0 Benign prostatic hyperplasia GA90 Approved [162]
Dutasteride + tamsulosin DM6P8HU Benign prostatic hyperplasia GA90 Phase 3 [19]
Besipirdine DMLVNTA Cognitive impairment 6D71 Phase 3 [163]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [34]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [138]
PMID30124346-Compound-LDT66 DMJMTNL Benign prostatic hyperplasia GA90 Patented [138]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [76]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Inhibitor [1]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Inhibitor [1]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [1]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Inhibitor [1]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Inhibitor [1]
5-HT 5A receptor (HTR5A) TTRUFDT 5HT5A_HUMAN Inhibitor [1]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Inhibitor [1]
5-HT 7 receptor (HTR7) TTO9X1H 5HT7R_HUMAN Inhibitor [1]
Adrenergic receptor alpha-1A (ADRA1A) TTNGILX ADA1A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-1B (ADRA1B) TTBRKXS ADA1B_HUMAN Inhibitor [1]
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2A (ADRA2A) TTWG9A4 ADA2A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2B (ADRA2B) TTWM4TY ADA2B_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2C (ADRA2C) TT2NUT5 ADA2C_HUMAN Inhibitor [1]
Adrenergic receptor beta-1 (ADRB1) TTR6W5O ADRB1_HUMAN Inhibitor [1]
Dopamine D1 receptor (D1R) TTZFYLI DRD1_HUMAN Inhibitor [1]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Inhibitor [1]
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Inhibitor [1]
Dopamine D4 receptor (D4R) TTE0A2F DRD4_HUMAN Inhibitor [1]
Dopamine D5 receptor (D5R) TTS2PH3 DRD5_HUMAN Inhibitor [1]
Histamine H2 receptor (H2R) TTQHJ1K HRH2_HUMAN Inhibitor [1]
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Inhibitor [1]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [1]

References

1 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
2 Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
3 Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
5 Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
6 Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
7 Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
8 Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
9 Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
10 Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
11 Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
12 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
14 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
15 Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
18 Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
19 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
20 Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
21 Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
22 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
23 Company report (NeurAxon)
24 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
25 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
26 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
27 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
28 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
29 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
30 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
31 alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
32 Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
33 Clinical pipeline report, company report or official report of Klus Pharma
34 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
35 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
36 Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
37 Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
38 Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994 Dec 5;355(3):242-6.
39 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
40 Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett. 1995 Dec 27;377(3):451-6.
41 Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol Pharmacol. 1993 Mar;43(3):313-9.
42 Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
43 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
44 Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. Eur J Pharmacol. 2001 Apr 27;418(3):157-67.
45 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
46 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
47 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
48 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
49 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
50 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
51 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
52 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
53 Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
54 Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
55 Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
56 Clinical pipeline report, company report or official report of Lundbeck.
57 A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
58 Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
59 trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
60 Clinical pipeline report, company report or official report of Lundbeck
61 Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
62 Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
63 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
64 Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
65 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
66 I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.
67 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
68 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
69 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
70 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
71 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
72 Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
73 Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
74 Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
75 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
76 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
77 An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
78 Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
79 Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
80 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
81 Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
82 Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
83 Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.
84 Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46.
85 Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol. 1995 Oct;48(4):774-82.
86 Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats. Arzneimittelforschung. 2001 Jan;51(1):46-50.
87 Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea. Arzneimittelforschung. 1993 Feb;43(2):129-33.
88 New and Future Drug Development for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2014 January; 20(1): 6-16.
89 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
90 Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
91 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
92 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
93 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
94 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
95 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
96 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
97 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
98 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
99 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
100 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
101 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
102 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
103 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
104 Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
105 Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
106 alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
107 Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
108 Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
109 Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
110 Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
111 Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
112 Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
113 Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
114 beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
115 beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
116 Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
117 Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.
118 Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
119 Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907.
120 Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
121 Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
122 Clinical pipeline report, company report or official report of signaturerx.
123 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
124 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
125 Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
126 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
127 Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
128 Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
129 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
130 The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
131 Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
132 Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
133 Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
134 Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
135 Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
136 The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
137 Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
138 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
139 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
140 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
141 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
142 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
143 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
144 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
145 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
146 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
147 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
148 Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
149 AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
150 Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
151 Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
152 [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
153 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
154 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
155 The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
156 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
157 Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
158 Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
159 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
160 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
161 Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
162 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
163 Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.